Abbott Laboratories (ETR:ABL)
Germany · Delayed Price · Currency is EUR | Market Cap | 185.72B |
| Revenue (ttm) | 36.71B |
| Net Income (ttm) | 11.86B |
| Shares Out | n/a |
| EPS (ttm) | 6.79 |
| PE Ratio | 15.66 |
| Forward PE | 23.00 |
| Dividend | 2.10 (1.96%) |
| Ex-Dividend Date | Jul 15, 2025 |
| Volume | 1,025 |
| Average Volume | 554 |
| Open | 107.10 |
| Previous Close | 106.48 |
| Day's Range | 107.10 - 107.70 |
| 52-Week Range | 90.00 - 134.14 |
| Beta | 0.74 |
| RSI | 39.43 |
| Earnings Date | Jul 16, 2025 |
About Abbott Laboratories
Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The company provides generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism,... [Read more]
Financial Performance
In 2024, Abbott Laboratories's revenue was $41.95 billion, an increase of 4.59% compared to the previous year's $40.11 billion. Earnings were $13.35 billion, an increase of 134.19%.
Financial numbers in USD Financial StatementsNews
Five years after COVID, pharma shares languish in US policy limbo
Global healthcare stocks have not been this cheap in decades and fund inflows into the sector are picking up, yet the shares remain in the doldrums, highlighting uncertainty over drug pricing policies...
Best Dividend Kings: July 2025
14 Dividend Kings continue to outperform the S&P 500 in 2025. Dividend growth remains healthy, with one recent increase and a collective 2025 growth rate of 5.23%. Seventeen Dividend Kings currently a...
Looking Into Abbott Laboratories's Recent Short Interest
Abbott Laboratories's (NYSE: ABT) short percent of float has fallen 5.83% since its last report. The company recently reported that it has 19.43 million shares sold short , which is 1.13% of all regu...
Analysts defend Abbott Labs' stock after Thursday's 'too punitive' sell-off
The Investing Club holds its "Morning Meeting" every weekday at 10:20 a.m. ET.
tech giants stumble as Tesla accelerates: Unpacking today's mixed market signals
📉 Technology Sector: Tech Giants Navigate Turbulence Today, the technology sector is showing signs of strain, with key players like Microsoft (MSFT) edging down by 0.17% and Oracle (ORCL) slipping by...
These Analysts Revise Their Forecasts On Abbott Following Q2 Results
Abbott Laboratories (NYSE: ABT) reported better-than-expected sales and profits in the second quarter, but dialed back earnings and growth projections for the rest of the year . The company reported ...
These Analysts Revise Their Forecasts On Abbott Following Q2 Results
Abbott Laboratories ABT reported better-than-expected sales and profits in the second quarter, but dialed back earnings and growth projections for the rest of the year.
Abbott Laboratories: What's Behind The Q2 Earnings Slump?
Microsoft To Rally More Than 14%? Here Are 10 Top Analyst Forecasts For Friday
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page . Jefferies...
Abbott CEO Robert Ford goes one-on-one with Jim Cramer
Abbott Chairman and CEO Robert Ford joins 'Mad Money' host Jim Cramer to talk quarterly results, lowering its full-year guidance, sale trends, and more.
Didn't see the recovery in China we were expecting, says Abbott Labs CEO on lowering guidance
Abbott Chairman and CEO Robert Ford joins 'Mad Money' host Jim Cramer to talk quarterly results, lowering its full-year guidance, sale trends, and more.
Abbott Laboratories CEO calls post-earnings stock decline 'a little bit of an overreaction'
Abbott Laboratories CEO Robert Ford unpacked his company's latest quarterly report in a Thursday interview with CNBC's Jim Cramer.
Abbott Laboratories (ABT) Q2 2025 Earnings Call Transcript
Abbott Laboratories (NYSE:ABT) Q2 2025 Results Conference Call July 17, 2025 9:00 AM ET Company Participants Michael Comilla - Vice President of Investor Relations. Philip P. Boudreau - CFO & Executi...
Abbott Narrows Its Outlook as COVID-19 Testing Demand Wanes. Its Stock Is Falling.
Abbott Laboratories shares slumped Thursday after the drugmaker narrowed its full-year outlook, even as it posted better-than-expected quarterly results, as demand for COVID-19 tests declines.
Tech sector rallies while healthcare faces downturn
Market Overview In today’s trading, tech stocks have emerged as the shining stars, displaying considerable gains against a backdrop of mixed sector performances. Conversely, the healthcare sector has ...
Abbott Laboratories Sheds Nearly 5% On A Rare Guidance Miss
Abbott stock toppled early Thursday after the health giant issued a light organic sales outlook for 2025, though beat quarterly calls.
Abbott Laboratories Issues Weak Earnings Forecast, Joins MP Materials And Other Big Stocks Moving Lower In Thursday's Pre-Market Session
U.S. stock futures were mostly lower this morning, with the Dow futures falling around 0.2% on Thursday. Shares of Abbott Laboratories (NYSE: ABT) fell sharply in pre-market trading after the company...
Abbott Laboratories Issues Weak Earnings Forecast, Joins MP Materials And Other Big Stocks Moving Lower In Thursday's Pre-Market Session
U.S. stock futures were mostly lower this morning, with the Dow futures falling around 0.2% on Thursday.
Abbott Laboratories falls after setting Q3 outlook below consensus
Abbott Labs Stock Dives After Earnings Miss. Why Rising Sales Fail to Lift Shares.
Abbott Labs Pares Outlook After Profit, Sales Gains
Abbott Laboratories (ABT) Q2 2025 sales and earnings beat estimates
Abbott Laboratories (NYSE: ABT) on Thursday announced financial results for the second quarter of fiscal 2025, reporting an increase in sales and adjusted profit. The results also exceeded Wall Street...
Abbott beats quarterly profit estimates on medical devices demand
Abbott beat Wall Street estimates for quarterly profit on Thursday, driven by strong demand for its medical devices including continuous glucose monitors.